Merck (MRK) Total Liabilities (2009 - 2026)
Merck (MRK) posted quarterly Total Liabilities of $128.7 billion for Q1 2026, up 11.78% year-over-year from $115.1 billion in Q1 2025, and down 5.98% quarter-over-quarter from $136.9 billion in Q4 2025.
Merck (MRK) Total Liabilities (2009 - 2026) Analysis & Trends
Merck (MRK) has reported Total Liabilities for 18 consecutive years, with $128.7 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Liabilities rose 11.78% year-over-year to $128.7 billion; the TTM figure through Mar 2026 stood at $128.7 billion (up 11.78% YoY), while the FY2025 annual figure was $136.9 billion, up 136766.0% from the prior year.
- Total Liabilities retreated to $128.7 billion in Q1 2026 per MRK's latest filing, from $136.9 billion in the prior quarter.
- Across five years, Total Liabilities topped out at $136.9 billion in Q4 2025 and bottomed at $100.0 million in Q4 2024.
- Historically, Total Liabilities has averaged $69.3 billion across 5 years, with a median of $107.1 billion in 2022.
- Annual changes were most pronounced in 2023 — Total Liabilities slumped 99.77% — and 2025, when it jumped 136766.0%.
- Merck's Total Liabilities stood at $600.0 million in 2022, then tumbled by 58.33% to $250.0 million in 2023, then slumped by 60.0% to $100.0 million in 2024, then surged by 136766.0% to $136.9 billion in 2025, then slipped by 5.98% to $128.7 billion in 2026.
- Business Quant data shows MRK's Total Liabilities at $128.7 billion in Q1 2026, $136.9 billion in Q4 2025, and $129.5 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 116.09 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 135.12 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 129.80 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 80.09 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 65.46 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 95.64 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 49.36 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 115.64 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | -59.79 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 150.01 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 129.80 Bn |
| Mar 31, 2026 | 128.69 Bn |
| Dec 31, 2025 | 136.87 Bn |
| Sep 30, 2025 | 129.55 Bn |
| Jun 30, 2025 | 117.52 Bn |
| Mar 31, 2025 | 115.12 Bn |
| Dec 31, 2024 | 100.00 Mn |
| Sep 30, 2024 | 117.53 Bn |
| Jun 30, 2024 | 112.63 Bn |
| Mar 31, 2024 | 125.00 Mn |
| Dec 31, 2023 | 250.00 Mn |
| Sep 30, 2023 | 250.00 Mn |
| Jun 30, 2023 | 104.47 Bn |
| Mar 31, 2023 | 125.00 Mn |
| Dec 31, 2022 | 600.00 Mn |
| Sep 30, 2022 | 107.08 Bn |
| Jun 30, 2022 | 107.10 Bn |
| Mar 31, 2022 | 600.00 Mn |
| Dec 31, 2021 | 400.00 Mn |
| Sep 30, 2021 | 93.49 Bn |